Title:
【発明の名称】黒色腫用免疫療法ワクチン
Document Type and Number:
Japanese Patent JPH04501663
Kind Code:
A
Abstract:
Immunotherapy vaccines are provided that are composed of disseminated melanoma tumor cell culture antigens and non-toxic, highly effective adjuvants including refined detoxified endotoxin such as monophosphoryl lipid A, and a biological immunostimulant such as mycobacterial cell wall skeleton, trehalose dimycolate, pyridine soluble extract of a microorganism and mixtures thereof, in a pharmaceutically acceptable carrier. By adding tumor antigens to potent but non-toxic immunostimulants, an effective active, specific vaccine for therapeutic and prophylactic purposes is produced. Allogeneic tumor antigens are produced as a cell lysate from a mixture of melanoma cells grown in a tissue culture and thereafter mechanically disrupted. The cell lysate is mixed with an adjuvant to form a vaccine. The vaccine is injected subcutaneously into a host in order to affect a melanoma tumor associated therewith. Cell lysates may be produced from cell lines MSM-M-1, ATCC No. CRL9822, and MSM-M-2, ATCC No. CRL9823.
Inventors:
Mitchell, Malcolm S.
Application Number:
JP51045089A
Publication Date:
March 26, 1992
Filing Date:
September 22, 1989
Export Citation:
Assignee:
UNIVERSITY OF SOUTHERN CALIFORNIA
International Classes:
C12N5/10; A61K39/00; A61K39/39; C12N5/08; C12P21/00; C12R1/91; (IPC1-7): A61K39/00; A61K39/39; C12N5/10; C12P21/00
Attorney, Agent or Firm:
Kyozo Yuasa (4 outside)